RNS Number : 9704T

Hutchison China Meditech Limited

31 March 2021

Total Voting Rights

Hong Kong, Shanghai, & Florham Park, NJ : Wednesday, March 31, 2021: Hutchison China MediTech Limited (" HUTCHMED" ) (AIM/Nasdaq: HCM) hereby notifies the market that as at March 31, 2021, the issued share capital of HUTCHMED consisted of 728,122,215 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no shares held in treasury.

The above figure of 728,122,215 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, HUTCHMED under the Financial Conduct Authority's Disclosure Rules and Transparency Rules.

For illustrative purposes only, the 728,122,215 ordinary shares would be equivalent to 728,122,215 CREST depositary interests (each equating to one ordinary share) which are traded on AIM or, if the CREST depositary interests were converted in their entirety, equivalent to 145,624,443 American depositary shares (each equating to five ordinary shares) which are traded on Nasdaq.


HUTCHMED (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has advanced ten cancer drug candidates from discovery into clinical studies around the world and has extensive commercial infrastructure in its home market of China. For more information, please visit: www.hutch-med.com .


Investor Enquiries 
  Mark Lee, Senior Vice President                            +852 2121 8200 
  Annie Cheng, Vice President                                +1 (973) 567 3786 
Media Enquiries 
  Americas - Brad Miles, Solebury Trout                      +1 (917) 570 7340 (Mobile) 
  Europe - Ben Atwell / Alex Shaw, FTI Consulting            +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 
                                                             545 055 (Mobile) 
  Asia - Joseph Chi Lo / Zhou Yi, Brunswick                  +852 9850 5033 (Mobile), jlo@brunswickgroup.com / +852 97 
                                                             83 6894 (Mobile), y zhou@brunswickgroup.com 
Nominated Advisor 
  Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) 
   Limited                                                   +44 (20) 7886 2500 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

March 31, 2021 02:00 ET (06:00 GMT)